Prolonged administration of CRH, or a CRH‐secreting tumor, leads to increases in corticotroph cell mass (Carey et al, 1984; Westlund et al, 1985; Schteingart et al, 1986; Gertz et al, 1987; Horvath, 1988; Asa et al, 1992; O'Brien et al, 1992) as well as ACTH output (Bruhn et al, 1984; Young & Akil, 1985). Here, CRH is linked to neoplasm.